Jascayd

nerandomilast · Boehringer Ingelheim International GmbH
AUTHORISED IN THE EU

What Jascayd is used for

Jascayd is indicated for the treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF). Jascayd is indicated for the treatment of adult patients with Progressive Pulmonary Fibrosis (PPF).

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Jascayd
Active substance
nerandomilast
Disease area
Idiopathic Pulmonary Fibrosis
Medicine group
Immunosuppressants
ATC code
L04AA61
Marketing authorisation holder
Boehringer Ingelheim International GmbH
Authorised in the EU since
2026

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Jascayd used for?

Jascayd is indicated for the treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF). Jascayd is indicated for the treatment of adult patients with Progressive Pulmonary Fibrosis (PPF).

What is the active substance in Jascayd?

Jascayd contains nerandomilast.

Who makes Jascayd?

The EU marketing authorisation holder is Boehringer Ingelheim International GmbH.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.